Merck & Co. Inc.

09/18/2021 | Press release | Distributed by Public on 09/18/2021 07:17

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line[...]